Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas
Francesco Marchesi, Fulvia Pimpinelli, Diana Giannarelli, et al.
Leukemia (2021) Vol. 36, Iss. 2, pp. 588-590
Open Access | Times Cited: 25

Showing 25 citing articles:

Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
Preetesh Jain, Michael Wang
American Journal of Hematology (2022) Vol. 97, Iss. 5, pp. 638-656
Closed Access | Times Cited: 90
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Livio Pagano, Jon Salmanton‐García, Francesco Marchesi, et al.
Blood (2022) Vol. 140, Iss. 26, pp. 2773-2787
Open Access | Times Cited: 69
Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies
G. Olivieri, Donato Amodio, Emma Concetta Manno, et al.
Vaccine (2025) Vol. 51, pp. 126853-126853
Open Access
Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review
Andrew Davies, Arnon P. Kater, Jeff P. Sharman, et al.
Future Oncology (2022) Vol. 18, Iss. 26, pp. 2943-2966
Open Access | Times Cited: 21
Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab
Erica Franceschini, Mariachiara Pellegrino, Vera Todisco, et al.
Infection (2023) Vol. 51, Iss. 5, pp. 1577-1581
Open Access | Times Cited: 10
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Noppacharn Uaprasert, Palada Pitakkitnukun, Nuanrat Tangcheewinsirikul, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 12
Open Access | Times Cited: 17
Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination
Deniz Can Güven, Taha Koray Şahin, Serkan Akın, et al.
The Oncologist (2022) Vol. 27, Iss. 4, pp. e357-e361
Open Access | Times Cited: 16
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies
Maryam Noori, Shadi Azizi, Farhan Abbasi Varaki, et al.
International Immunopharmacology (2022) Vol. 110, pp. 109046-109046
Open Access | Times Cited: 14
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia
Milena Kohn, Marc Delord, Maureen Chbat, et al.
Haematologica (2021) Vol. 107, Iss. 6, pp. 1454-1459
Open Access | Times Cited: 15
The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic
Marta Canuti, Maria Cristina Monti, Chiara Bobbio, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 5
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia
Zoë L. Lyski, Myung Sun Kim, David X. Lee, et al.
Blood Advances (2021) Vol. 6, Iss. 4, pp. 1207-1211
Open Access | Times Cited: 13
Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies
Amy C Sherman, Jennifer L. Crombie, Chi‐An Cheng, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 8
Open Access | Times Cited: 9
Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies
Mihaela Andreescu
Cureus (2024)
Open Access | Times Cited: 1
Immunogenicity of COVID-19 Vaccinations in Hematological Patients: 6-Month Follow-Up and Evaluation of a 3rd Vaccination
Lorenz Schubert, Maximilian Koblischke, Lisa Schneider, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 1962-1962
Open Access | Times Cited: 7
Anti-spike antibody response to the COVID vaccine in lymphoma patients
Alexandra Della Pia, Gee Youn Kim, Andrew Ip, et al.
PLoS ONE (2022) Vol. 17, Iss. 12, pp. e0266584-e0266584
Open Access | Times Cited: 5
Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies
Mihaela Andreescu
Life (2023) Vol. 13, Iss. 6, pp. 1272-1272
Open Access | Times Cited: 2
Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination
Carol Gung, Regina McGuire, Mercy George, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 4
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects
Valentina Laquintana, Carla Mottini, Francesco Marchesi, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access
Unbiased immunome characterisation correlates with COVID-19 mRNA vaccine failure in immunocompromised adults
Juan H-Vázquez, Paloma Cal-Sabater, Elisa Arribas‐Rodríguez, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report
Federica Calò, Lorenzo Onorato, Mariantonietta Pisaturo, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1021-1021
Open Access | Times Cited: 3
Different Clinical Outcomes of COVID-19 in Two Healthcare Workers Vaccinated with BNT162b2 Vaccine, Infected with the Same Viral Variant but with Different Predisposing Conditions for the Progression of the Disease
Loredana Alessio, Mariantonietta Pisaturo, Antonio Russo, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 298-298
Open Access | Times Cited: 2
Production of anti-spike antibodies in response to COVID vaccine in lymphoma patients
Alexandra Della Pia, Gee Youn Kim, Andrew Ip, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 2
Unbiased spectral cytometry immunome characterization predicts COVID-19 mRNA vaccine failure in older adults and patients with lymphoid malignancies
Juan H-Vázquez, Paloma Cal-Sabater, Elisa Arribas‐Rodríguez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Multicenter cohort study of the risk factors and mortality of Omicron variant SARS-CoV-2-infected patients with hematologic malignancies in hospitals
Xiangping Zong, Jin Zhou, Xiao Ma, et al.
Research Square (Research Square) (2023)
Open Access
Cellular and humoral Immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia
Zoë L. Lyski, Myung Sun Kim, David X. Lee, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access
Page 1

Scroll to top